Molecular characterization of non-small cell lung cancer (NSCLC) marked an historical
turning point for the treatment of lung tumors harboring kinase alterations suitable for …

Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic
paradigm shift over the past decade. Advances in our understanding of the underlying …

Introduction Approximately 2% of lung adenocarcinomas have BRAF (v-Raf murine sarcoma
viral oncogene homolog B) mutations, including V600E and other types. Vemurafenib …

Background: Several subsets of non–small-cell lung cancer (NSCLC) are defined by
molecular alterations acting as tumor drivers, some of them being currently therapeutically …

Several targetable genetic alterations have been found in lung cancer, predominantly in
adenocarcinomas, which have led to important therapeutic advancements with the advent of …

Lung cancer harbouring BRAF mutations accounts for 4% of all non-small cell lung cancer
(NSCLC) cases, identifying a relevant subset of patients that need to be promptly managed …

Gain-of-function of V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) is one of the
most frequent oncogenic mutations in numerous cancers, including thyroid papillary …

Background. Although genetic profiling of tumors is a potentially powerful tool to predict drug
sensitivity and resistance, its routine use has been limited because clinicians are often …

We report a patient with a metastatic relapse of clear cell sarcoma, whose tumor harbored
BRAF V600E mutation. Standard chemotherapy with doxorubicin and ifosfamide failed to …

Lung adenocarcinoma includes recurrent activating oncogenic mutations (EGFR, EML4-
ALK, ROS1) that have been associated with response to EGFR and ALK inhibitors. Platinum …